Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows

Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows
A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. The trial, sponsored by the National Cancer Institute, also showed that the combination significantly extends the time to disease progression or death. A trend toward better survival rates was seen, but the trial was not powered to detect significant differences in this outcome. The findings were recently presented at the 17th Biennial Meeting of the International Gynecological Cancer Society (IGCS) in Kyoto, Japan. The research was titled "NRG Oncology Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Ovarian Cancer." Immune checkpoint inhibitors, or medicines that boost the immune system to attack cancer cells more efficiently, have been at the forefront of cancer treatment for the past five years. These medicines are approved for multiple cancer types, including melanoma, lung cancer, head and neck cancer, kidney cancer, and bladder cancer. But to date, no immune checkpoint inhibitor has been approved for ovarian cancer patients. Opdivo, a medicine that blocks the interaction of PD-1 with its ligands PD-L1 and PD-L2, has shown promise in patients with advanced ovarian cancer who are resistant to platinum-based chemotherapy. In a Phase 2 trial, 15 percent of pa
Subscribe or to access all post and page content.